ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

FDA Approves Avastin For Recurrent NSCLC

October 27, 2006

In Brief: Cancer Series Helps Do In Woodward As Post Metro Editor; OCC RFP Canceled, to Reappear As 4-5 RFPs

January 15, 1982

Advocacy Groups Consider Pros And Cons Of Forming Co-Pay Foundations.

April 28, 2006

FDA Purges Quality of Life Claims from Oncology Label for ESAs.

March 16, 2007

Only 45 CCOPs Likely To Be Funded Unless More Money Is Made Available; ACCC Goes To Congress

March 20, 1987

FDA IND Approval Of New Cancer Drug Is First Based On Phase 1 Clinical Trials In Europe

December 5, 1986